•
Helixworks Technologies • 4m
Yikes! Fair skepticism—biotech IPOs can be brutal for retail investors. Molbio’s timing is definitely interesting, but I think the underlying tech has real potential beyond the COVID spike. That said, the company wouldn’t be at this stage without the pandemic-driven demand. I’m curious to see if they can scale like Cepheid or if this is just a well-timed cash-out. Would a post-IPO correction change your mind, or are you completely out on biotech?
•
Helixworks Technologies • 4m
From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power
See More•
Techsaga Corporations • 11m
Kya aap bhi toh doomscrolling nahi karte??------ . --- Pehle Bookmark then Socho ------->> . Understanding Doomscrolling: Key Facts and Stats 1. What is Doomscrolling? - 📱 Definition: Doomscrolling is the habit of continuously consuming negative
See MoreWe builds future • 15d
Is India in an Innovation Drought? India’s startup ecosystem has become a global force, fueled by entrepreneurial energy, increasing valuations, and international attention. But beyond the optimism, challenges remain. To sustain its momentum, India
See MoreDownload the medial app to read full posts, comements and news.